Compare PepsiCo, Inc. (PEP) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs TransMedics Group Inc — how do they compare? PepsiCo, Inc. trades at $137.21 (market cap $186.57B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: PepsiCo, Inc. is far larger — about 62.2× TransMedics Group Inc's market cap, and PepsiCo, Inc. pays a 4.33% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| PEP | TMDX | |
|---|---|---|
Market Cap | $186.57B | $3.00B |
Sector | Consumer Staples | Technology |
52-Week High | $170.44 | $150.42 |
52-Week Low | $134.95 | $61.99 |
Enterprise Value | $229.07B | $3.39B |
Dividend Yield | 4.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $138.45, up 0.6% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with a 10.78% net margin and 51.59% ROE, though recent earnings beat expectations. Revenue grew to $93.93B in 2025, with a forward consensus price target of $158.79. Recent news highlights price cuts on snacks to address consumer pushback and a sponsorship withdrawal from a music festival.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside, but technical bearishness and pricing strategy risks weigh. Investment appeal hinges on execution of North American turnaround and margin expansion. Key risks include competitive pressures and volatile cash flows. The stock offers a dividend yield near 4%, appealing for income-focused investors amid steady growth prospects.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
